CoChat

Omega-3 Fatty Acids and Skeletal Muscle Health

Open access

The DOI matches its Crossref record; 179 of the 180 references it cites were found in a registry or an index; 68 of the 207 sources its claims cite were checked for support.

Abstract

Skeletal muscle is a plastic tissue capable of adapting and mal-adapting to physical activity and diet. The response of skeletal muscle to adaptive stimuli, such as exercise, can be modified by the prior nutritional status of the muscle. The influence of nutrition on skeletal muscle has the potential to substantially impact physical function and whole body metabolism. Animal and cell based models show that omega-3 fatty acids, in particular those of marine origin, can influence skeletal muscle metabolism. Furthermore, recent human studies demonstrate that omega-3 fatty acids of marine origin can influence the exercise and nutritional response of skeletal muscle. These studies show that the prior omega-3 status influences not only the metabolic response of muscle to nutrition, but also the functional response to a period of exercise training. Omega-3 fatty acids of marine origin therefore have the potential to alter the trajectory of a number of human diseases including the physical decline associated with aging. We explore the potential molecular mechanisms by which omega-3 fatty acids may act in skeletal muscle, considering the n-3/n-6 ratio, inflammation and lipidomic remodelling as possible mechanisms of action. Finally, we suggest some avenues for further research to clarify how omega-3 fatty acids may be exerting their biological action in skeletal muscle.

Overview

CoChat Summary

TL;DR

This narrative review argues that marine omega-3 PUFAs (EPA/DHA) can influence skeletal muscle metabolism, anabolism, insulin sensitivity, inflammation, and lipidome remodelling, with human evidence strongest for enhanced muscle protein synthesis and some functional benefits. It concludes that human trial results remain mixed, likely due to high n-6/n-3 ratios, individual variation, and unresolved dose/placebo issues.

Key findings

  • Human RCTs: 8-week supplementation with 1.86 g EPA + 1.5 g DHA/day augmented the muscle protein synthesis response to a hyperinsulinemic-hyperaminoacidemic clamp in older adults without affecting basal MPS, with a similar trend in young/middle-aged individuals; 6 months of 1.8 g EPA + 1.5 g DHA/day ameliorated age-related declines in lean muscle mass and increased hand grip and 1-RM strength. A 90-day trial of 2 g/day omega-3 plus progressive resistance exercise improved strength and neuromuscular function, but omega-3 alone had no effect.
  • In C2C12 myotubes, EPA increased MPS 25% greater than control, while DHA had no effect despite elevated p70S6K1 phosphorylation in both treatments; EPA may reduce protein degradation via NF-κB/MURF-1 signalling, and one study found DHA attenuated degradation more efficiently than EPA.
  • Metabolic/insulin findings: 3 weeks of omega-3 supplementation increased fat oxidation by 35% at the expense of glucose utilization after a glucose bolus, but human glucose homeostasis trials are equivocal, with some showing no effect or adverse effects. Proposed protective mechanisms include increased incorporation of fatty acids into complex lipids, reduced inflammatory signalling, and PPARγ/NF-κB effects.
  • Inflammation/lipidome: EPA-derived eicosanoids are up to 50%–80% less biologically active than arachidonic acid-derived eicosanoids; the threshold for EPA to reduce prostaglandin E2 was between 1.35 and 2.75 g/day, and muscle total lipid/phospholipid omega-3 enrichment increased approximately two-fold over 4–12 weeks of supplementation.

Methods

  • Narrative review synthesizing animal, cell-based, and human studies on omega-3 PUFAs and skeletal muscle health, including two summary tables of studies.
  • No systematic search strategy, inclusion criteria, risk-of-bias assessment, or meta-analysis is described (evident from the text).
  • Main analysis is a qualitative synthesis of proposed mechanisms: muscle anabolism, metabolic flexibility/insulin resistance, inflammation, and lipidome remodelling.

Limitations

  • Stated: human trial results are equivocal; no consensus exists on an effective omega-3 dose, there is no apparent dose-response relationship, and individual variation in tissue uptake/lipidomic response may mask effects.
  • Stated: placebo choice is key; high omega-6 corn oil controls may have metabolic effects and may not represent a true placebo, and the authors hypothesize that a high n-6/n-3 ratio limits omega-3 effects.
  • Evident: as a narrative review, it does not systematically appraise study quality, and many mechanistic conclusions derive from cell or rodent models and remain to be confirmed in human skeletal muscle.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/md13116977

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Highlights some of the mechanisms of action by which omega-3 PUFAs EPA and DHA may influence skeletal muscle health and function.
Figure 1 Highlights some of the mechanisms of action by which omega-3 PUFAs EPA and DHA may influence skeletal muscle health and function.CC BY · PubMed Central

Verification

Claims the paper makes

47 Valid · 7 Not valid · 82 Not checked · 54 Own results and interpretations

96 more claims · 33 with their cited sources checked

Create a free account to see all 190 claims and to verify the 139 references still open.

See all claims — free account
  • It may state two separate claims as one. 78
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Cited by

See all 203

Metadata

Authors
Jeromson, S., Gallagher, I., Galloway, S., & Hamilton, D.
Affiliations
University of Stirling (GB)
Corresponding author
Hamilton, D.
Venue
Marine Drugs
Publisher
MDPI AG
Published
2015-11-19
Volume
13
Issue
11
Pages
6977-7004
ISSN
1660-3397 (ISSN-L)
OpenAlex
W2174795486
Cited by
203
References
180
Citations by year
2026: 20 · 2025: 20 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 20 · 2020: 30 · 2019: 22 · 2018: 21 · 2017: 11 · 2016: 6
FWCI
1.63
Type
journal article
Language
en
Open access
Locations
  • Marine Drugs (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Own your potential (DEAKIN) (submittedVersion)
  • Stirling Online Research Repository (University of Stirling) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
  • Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
Keywords
omega-3 fatty acids, skeletal muscle, muscle metabolism, exercise training response, n-6/n-3 ratio, inflammation, aging, physical function, muscle plasticity
MeSH terms
Aging, Animals, Humans, Inflammation, Fatty Acids, Omega-3, Muscle, Skeletal, Aquatic Organisms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.